Group 1: Dana Biological - Dana Biological, established on March 10, 2014, focuses on early diagnosis of invasive fungal diseases and other pathogen microbiological in vitro diagnostic products [2] - The company is recognized as a national high-tech enterprise and a key specialized "little giant" enterprise supported by the state [2] - The initial public offering (IPO) price is set at 17.10 CNY per share, with a projected earnings per share (EPS) of 11.75, significantly lower than the industry average of 31.59 [3] - In 2022, Dana Biological held approximately 30% market share in China's invasive fungal disease diagnostic reagent market [4] - The company’s main products include reagents for invasive fungal disease diagnosis, with reagent products accounting for 90.52% of its main business revenue in 2024 [4] - Dana Biological has sufficient inventory of horseshoe crab blood cells to meet production needs for over five years and is actively exploring overseas procurement channels [5] Group 2: Marco Polo - Marco Polo specializes in the research, production, and sales of building ceramics, being one of the largest manufacturers in China [6] - The IPO price is set at 13.75 CNY per share, with a market capitalization of 164.30 billion CNY [7] - The company’s revenue from 2022 to 2024 is projected to be 86.61 billion CNY, 89.25 billion CNY, and 73.24 billion CNY respectively, maintaining its position as the top player in the building ceramics industry [6][10] - Marco Polo's main business includes glazed and unglazed tiles, with glazed tile revenue increasing from 82.95 billion CNY in 2022 to 71.50 billion CNY in 2024, while unglazed tile revenue is decreasing [10] - The company has a dual sales model of "distribution + direct sales," with significant clients including major real estate companies [9][10] - Marco Polo's revenue is closely tied to the real estate market, which has shown volatility, impacting its performance [11]
国保动物作原料！病原微生物诊断龙头今日申购 另有一只新股上市丨打新早知道